Altimmune (ALT) vs Lifecore Biomedical (LFCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Lifecore Biomedical (LFCR) has outperformed Altimmune (ALT) over the past year, losing 16.4% versus a loss of 72.3%. Over five years, LFCR leads with a -26.3% price change compared with -87.2% for ALT. Altimmune is the larger company by market cap ($258.8 million vs $242.2 million), about 1.1 times the size.
Lifecore Biomedical converts more of its revenue into profit, with a net margin of -30.0% versus -214861.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALT | LFCR |
|---|---|---|
| Share price | $1.33 | $6.39 |
| Market cap | $258.80M | $242.22M |
| 1-day change | -5.67% | +0.31% |
| YTD return | -63.16% | -21.88% |
| 1-year return | -72.35% | -16.36% |
| 5-year return | -87.24% | -26.30% |
| EPS (TTM) | $-0.71 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $41.00K | $128.87M |
| Revenue growth (YoY) | +105.00% | +0.47% |
| Net income (latest FY) | $-88.09M | $-38.72M |
| Gross margin | — | 31.27% |
| Operating margin | -230460.98% | -13.38% |
| Net margin | -214860.98% | -30.04% |
| 52-week high | $6.44 | $8.98 |
| 52-week low | $1.32 | $3.63 |
| Distance from 52-week high | -79.35% | -28.84% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +1127.82% | -1.72% |
| Average volume | 3.91M | 414.71K |
| Shares outstanding | 194.59M | 37.91M |
| Employees | 57 | 382 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LFCR has outperformed ALT by 56.0 percentage points over the past year.
- Lifecore Biomedical is more profitable, keeping -30.0 cents of every revenue dollar as net income versus -214861.0 cents for Altimmune.
- Altimmune grew revenue faster in its latest fiscal year (+105.00% vs +0.47%).
About Altimmune
ALT stock →Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
About Lifecore Biomedical
LFCR stock →Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities.
Health Care · Biotechnology: Pharmaceutical Preparations · 382 employees
ALT vs LFCR FAQ
Which is bigger, Altimmune or Lifecore Biomedical?
Altimmune (ALT) is larger, with a market capitalization of $258.80M compared with $242.22M for Lifecore Biomedical (LFCR).
Which stock has performed better over the past year, ALT or LFCR?
LFCR returned -16.36% over the past 12 months, compared with -72.35% for ALT (price return, excluding dividends). Past performance does not predict future results.
Are Altimmune and Lifecore Biomedical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.